Aclaris Therapeutics vs HCW Biologics
ACRS and HCWB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and HCWB compare
Aclaris Therapeutics is the larger company, worth 361 times as much as HCW Biologics ($531M against $1.5M).
HCW Biologics grew revenue faster over the last twelve months (700% versus −51.0% for Aclaris Therapeutics).
HCW Biologics keeps more of each dollar of sales as profit, with a net margin of −83.8% compared with −921% at Aclaris Therapeutics.
HCW Biologics scores higher on the StockData Score (6 against 5 for Aclaris Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | HCWB |
|---|---|---|
| Size and price | ||
| Market cap | $531M | $1.5M |
| Share price | $3.60 | $0.800 |
| Change, 1 year | 55.4% | −94.6% |
| Change, 5 years | −71.4% | −99.9% |
| Beta (5Y) | 0.96 | 2.44 |
| Employees | 73 | – |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 64.6× | 0.2× (better) |
| P/B | 4.3× | 0.2× (better) |
| FCF yield | −11.7% | – |
| Fair value | $1.42 | $15.29 |
| Margin of safety | −155% | 94.8% (better) |
| Growth | ||
| Revenue growth (TTM) | −51.0% | 700% (better) |
| Revenue growth, 5Y average | 3.8% (better) | −57.9% |
| Profitability | ||
| Gross margin | 79.5% | 96.7% (better) |
| Operating margin | −1050% | −115% (better) |
| Net margin | −921% | −83.8% (better) |
| FCF margin | −757% | – |
| Return on equity | −59.1% (better) | −151% |
| Return on invested capital | – | −70.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.88 (better) |
| Interest coverage | – | −14.0× |
| Current ratio | 3.46 (better) | 0.06 |
| Altman Z-score | −3.16 (better) | −7.20 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 5.6% |
| Held by insiders | 13.3% | 34.9% |
| Insider net buying, 12 months | −$1.4M | $532K (better) |
| Short interest, % of float | 9.1% | 4.1% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- HCWB stock overview
- HCWB income statement
- HCWB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.